$CRL · CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Charles River reported Q3 FY2026 (ended Sept 26, 2026) results: revenue $982.7M (down 2.2% reported, +4.7% organic), GAAP EPS $6.86, non-GAAP EPS $3.09. GAAP net income of $333.1M included a $245.6M ($5.06/share) benefit from reversal of acquired tax reserves. Non-GAAP operating margin rose 330bps to 23.0%. The company raised 2026 guidance: organic revenue growth to at least +1.5% and non-GAAP EPS to $11.35–$11.55.
- Non-GAAP EPS rose 27.2% YoY to $3.09 from $2.43.
- Organic revenue grew 4.7%, second consecutive quarter of organic growth.
- GAAP EPS of $6.86 included a $5.06/share tax-reserve reversal benefit.
- 2026 non-GAAP EPS guidance raised by $0.15 at midpoint to $11.35–$11.55.
- DSA segment organic revenue grew 5.9% on higher safety-assessment study volume.
Extended-hours last trade $362.00, up 2.88% vs the $351.87 regular close, reflecting a positive reaction to the beat and guidance raise.
A second straight quarter of organic growth plus a guidance raise confirms the biopharma demand recovery thesis for the CRO leader.
The return to organic growth and DSA bookings strength signals improving biopharma R&D demand, a positive read-through for the CRO/preclinical services peer group.
Reported revenue still declined 2.2% due to divestitures, and RMS organic revenue fell 0.6% on weaker small/large research model demand.